Executive Summary
Non-invasive imaging techniques, including MRI and PET, are central to implementing the 3Rs framework in preclinical research. These modalities enable longitudinal data collection from individual subjects, directly supporting the principle of Reduction by decreasing the total number of animals required for a study. They also advance Refinement by minimizing procedural stress and providing real-time guidance for precise therapeutic delivery. This approach generates more robust, translatable data sets that align with UK Home Office and AAALAC International standards for animal welfare while strengthening IND-enabling packages.
Frequently Asked Questions
Q: How does non-invasive imaging support the 3Rs in preclinical research?
A: It enables longitudinal data acquisition from a single animal, reducing cohort sizes (Reduction). It also refines procedures by minimizing physical stress and invasiveness, which improves data quality and animal welfare (Refinement).
Q: What specific imaging modalities does Franklin Biolabs use for these studies?
A: We deploy a range of modalities tailored to the research question and therapeutic agent, including Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Computed Tomography (CT), and various optical imaging systems.
Q: Are these imaging techniques GxP compliant for IND-enabling studies?
A: Yes. Our imaging protocols, data acquisition, and analysis are executed within a GxP framework to ensure the data integrity required for regulatory submissions.
Q: How does MRI-guided delivery refine preclinical procedures?
A: MRI-guided systems permit real-time, high-precision administration of therapeutic agents to specific anatomical targets. This minimizes procedural variability and enhances data consistency, directly supporting the principle of Refinement.
Integrating Advanced Imaging with Animal Welfare Standards
In the United Kingdom, all in vivo research is governed by the Animals (Scientific Procedures) Act 1986, which legally mandates the application of the 3Rs: Replacement, Reduction, and Refinement. For complex biologic programs, achieving robust, IND-enabling data while adhering to these principles requires sophisticated operational models. Non-invasive imaging provides a direct mechanism to meet these dual objectives.
By conducting longitudinal studies, we can monitor disease progression and therapeutic response within the same subject over time. This eliminates the need for large, staggered cohorts with terminal endpoints at each time point, significantly reducing the total number of animals used in a program. This methodology produces more statistically powerful data, as it minimizes the biological variability inherent between subjects.
Enhanced Responsibility in Practice
Our commitment to these principles is integrated into every aspect of our GxP-compliant operations.
- To view the complete program, visit: *
Precision Delivery as a Form of Refinement
Advanced imaging extends beyond observation to active procedural refinement. As demonstrated in recent technical literature (PMID: 38310346), MRI-guided frameless stereotactic systems enable highly accurate, real-time delivery of viral vectors to precise anatomical locations. This technique minimizes the need for exploratory procedures and reduces variability, ensuring the therapeutic agent is delivered exactly as intended. The result is higher-quality, more reproducible data from each animal, a core tenet of Refinement.
At our >100,000 sq ft facility, we apply these principles to de-risk development programs. By generating better data from fewer animals, we build stronger regulatory packages. This operational agility accelerating in vivo success has contributed to our 100% IND application success rate for studies conducted since 2019. (The Franklin Biolabs brand launched in 2024.) This focused approach helps sponsors navigate the typical 18-24 month timeline from candidate selection to IND filing with greater confidence.
- Sub-Tagline: Precision Imaging. Principled Research.*
Technical Visualization: Evolution of In Vivo Study Design via the 3Rs
svg“`
